Saltar ao contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Title
Autor
Subject
Número de Clasificación
ISBN/ISSN
Tag
Buscar
Avanzado
The Rapamycin Derivative RAD00...
Citar
Text this
Enviar este rexistro por email
Imprimir
Exportar rexistro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Permanent link
The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
Detalles Bibliográficos
Main Authors:
Grozinsky-Glasberg, S
,
Rubinfeld, H
,
Gorshtein, A
,
Prais, M
,
Kendler, E
,
Feinmesser, R
,
Grossman, A
,
Shimon, I
Formato:
Conference item
Publicado:
2009
Existencias
Descripción
Títulos similares
Staff View
Títulos similares
The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
por: Grozinsky-Glasberg, S, et al.
Publicado: (2010)
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
por: Grozinsky-Glasberg, S, et al.
Publicado: (2008)
The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
por: Grozinsky-Glasberg, S, et al.
Publicado: (2011)
Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
por: Druce, MR, et al.
Publicado: (2009)
Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
por: Druce, M, et al.
Publicado: (2012)